Last reviewed · How we verify
Fluoxétine and Budésonide
Fluoxetine is a selective serotonin reuptake inhibitor (SSRI) and budesonide is a corticosteroid.
Fluoxetine is a selective serotonin reuptake inhibitor (SSRI) and budesonide is a corticosteroid. Used for Major depressive disorder, Asthma.
At a glance
| Generic name | Fluoxétine and Budésonide |
|---|---|
| Sponsor | ANRS, Emerging Infectious Diseases |
| Drug class | SSRI, corticosteroid |
| Target | Serotonin transporter, glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Psychiatry, Respiratory |
| Phase | Phase 2 |
Mechanism of action
Fluoxetine works by increasing the levels of serotonin in the brain, which can help improve mood and reduce symptoms of depression. Budesonide, on the other hand, is a corticosteroid that reduces inflammation in the body.
Approved indications
- Major depressive disorder
- Asthma
Common side effects
- Nausea
- Headache
- Insomnia
- Diarrhea
- Vomiting
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fluoxétine and Budésonide CI brief — competitive landscape report
- Fluoxétine and Budésonide updates RSS · CI watch RSS
- ANRS, Emerging Infectious Diseases portfolio CI